IOL Chemicals & Pharmaceuticals Ltd Q2 FY26 – Painkillers, Profits & Paracetamol: How India’s Ibuprofen King Is Fighting Its Mid-Life Crisis
1. At a Glance
Imagine being the world’s biggest supplier of painkillers, yet feeling the pain yourself every quarter — that’s IOL Chemicals & Pharmaceuticals Ltd (IOLCP) for you. Trading at ₹97.3 a share, the Bathinda-based company has a market cap of ₹2,857 crore, and just pulled off a 56.7% jump in quarterly profit. Q2 FY26 revenue stood at ₹568 crore, with ₹30 crore PAT and a steady operating profit margin of 10%.
While that 35% global share in Ibuprofen still makes them the pain relief monarch, IOLCP’s real headache has been growth. Sales are up only 5.7% YoY and profits after tax have crawled to ₹116 crore in FY25 from ₹135 crore in FY24 — respectable, but not the stuff of legend. The P/E ratio sits at 24.6, EV/EBITDA at 11.3, and debt is minimal at ₹159 crore. Dividend yield? A mild 0.78%, because clearly, they prefer R&D over retail investor therapy.
Still, a 15% one-year return isn’t bad for a company that sells the stuff you pop after reading its balance sheet.
2. Introduction – The Global Painkiller Who Needs a Painkiller
In the pharmaceutical jungle, IOLCP is that veteran elephant who’s both wise and weary. Known worldwide for Ibuprofen — yes, the same pill your dad swears by after a wedding buffet — the company has been fighting off global price erosion, competition from China, and the curse of single-product dependence.
But hold on — this isn’t another sob story. Because in FY25 and beyond, IOLCP seems to have woken up to a new prescription: diversify or die. Non-ibuprofen APIs now account for 34% of the API business, up from just 14% five years ago. They’ve added Metformin, Clopidogrel, Paracetamol, Pantoprazole, and Lamotrigine to their growing medical grocery list.
From a sleepy Punjab-based chemical outfit, IOLCP now serves 80 countries. Think of them as the small-town kid who’s now selling painkillers in Switzerland, antidiabetics in the UK, and paracetamol to the EU — all while trying to manage compliance, EU audits, and Punjab weather.
Yes, the CEO resigned in September 2024, but don’t panic — the Ibuprofen machines didn’t.
3. Business Model – WTF Do They Even Do?
Two legs, one backbone, and a headache. That’s IOLCP’s structure.
1. Pharmaceuticals (57% of H1 FY25 revenue) This is the glamorous side — APIs or Active Pharmaceutical Ingredients. Basically, the chemical heartbeats that big pharma companies use to make your tablets. IOLCP leads the world in Ibuprofen production (12,000 MTPA capacity, 35% market share globally) and dominates India’s Metformin space. They’ve also built a healthy pipeline in Clopidogrel (for heart disease) and Pantoprazole (for acidity — because finance meetings cause reflux).
2. Chemicals (43% of revenue) The not-so-glamorous but money-spinning cousin. Here, IOLCP makes specialty chemicals like Ethyl Acetate, Iso Butyl Benzene (IBB), and Acetic Anhydride — the building blocks for industries like pharma, textiles, and inks. These chemicals often feed back into their API operations, making IOLCP a vertically integrated player.
Integration is their secret sauce: they manufacture their own intermediates, reducing dependence on imports and Chinese suppliers.
In short — they’re not just selling Ibuprofen; they’re selling the ingredients for it too. That’s like owning both the pizza and the cheese factory.
4. Financials Overview
Metric
Latest Qtr (Q2 FY26)
YoY Qtr (Q2 FY25)
Prev Qtr (Q1 FY26)
YoY %
QoQ %
Revenue
₹568 Cr
₹526 Cr
₹552 Cr
8.0%
2.9%
EBITDA
₹64 Cr
₹42 Cr
₹62 Cr
52.3%
3.2%
PAT
₹30 Cr
₹19 Cr
₹34 Cr
57.9%
-11.8%
EPS (₹)
1.02
0.65
1.16
57.9%
-12.1%
Commentary: Revenue’s up, profit’s up, and OPM at 10% feels stable. But that QoQ dip in PAT hints that the Q1 sugar rush might be fading. Annualized EPS comes to ₹4.08, giving us a P/E of around 23.9 — decent for a midcap pharma player, though still behind the big-league Ciplas and Dr
